Top Markets
Coin of the day
Novogene Co., Ltd. Novogene Co., Ltd.

Novogene Co., Ltd.

688315
株式のランク #9857
Novogene Co., Ltd. is a global provider of comprehensive genomic services and... Novogene Co., Ltd. is a global provider of comprehensive genomic services and advanced solutions. Its offerings span a wide array of genomic applications, including human, animal, plant, and microbial genome sequencing, alongside gene regulation and single-cell sequencing technologies. The company also specializes in cancer genomic profiling, whole exome sequencing (including clinical-grade versions), and FFPE RNA sequencing. Furthermore, Novogene develops proprietary tools such as NovoFocus, a next-generation sequencing (NGS)-based companion diagnostic for PARP inhibitor treatments, and NovoNeoantigen, a bioinformatics pipeline that identifies cancer neoantigens by analyzing whole exome and whole transcriptome sequencing data from matched tumor and normal samples. In a strategic collaboration, Novogene partners with Hummingbird Bioscience Pte. Ltd. to aid in the advancement of HMBD-001. This investigational anti-HER3 antibody is being assessed for its potential to treat diverse cancer types, notably those driven by NRG1-fusion. Established in 2011, Novogene Co., Ltd. operates from its headquarters in Beijing, China.
株価
$2.25
最終同期: 2026-08-28
時価総額
$936.66M
変化(1日)
-3.18%
変化(1年)
3.07%
CN
取引 Novogene Co., Ltd. (688315)

カテゴリー

Novogene Co., Ltd.(688315)の利益
2026 時点の利益 TTM: 0
Novogene Co., Ltd. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Novogene Co., Ltd. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH